ICD10BillableValid for clinical use

ICD-10 Code E88.12: Generalized lipodystrophy

E88.12 is a billable ICD-10 diagnosis code used to classify Generalized lipodystrophy in medical records and claims. You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records. ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

What is this code?

ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

šŸ“‹Clinical overview

This entry records generalized lipodystrophy, with both acquired and congenital contexts included in the stored classification. Generalized does not by itself mean congenital, a particular gene, a known age of onset or an identical set of complications in every person. The original acquired generalized, congenital generalized, Berardinelli-Siep and Lawrence inclusions remain visible as recorded. The code supplies neither a laboratory measurement nor a personal treatment indication. Its meaning should be explained with the actual clinical account, while the original coding, hierarchy, Index and related-service information remain intact.

When is it used?

  • May be used when a clinician documents generalized lipodystrophy in a patient's medical record.
  • May appear in hospital records, claims, referrals, and clinical documentation.
  • This code can be used as a clinically usable diagnosis entry in standardized coding workflows.

What it does not mean

  • A code alone does not explain severity, treatment plan, or outcome.
  • A medical code should not be treated as a substitute for a doctor's diagnosis or advice.

🩺Clinical context

When commonly used
  • Generalized distinguishes this classification from partial and localized entries; it is not a measurement of how much fat is present or a numerical severity score. The title cannot establish that every body region has identical changes or that a condition has been present since birth. Ask whether the clinician documented an acquired or congenital context and what supports that interpretation. An inclusion term, an associated parent concept or a general source's description cannot establish a reader's precise phenotype, genotype, age of onset or current organ findings.
  • The NLM congenital-generalized resource describes widespread lack of adipose tissue, often recognized early in life, with more than one genetic cause and variable associated features. That congenital background should not be imposed on all generalized cases, because the stored entry also includes an acquired form. The older NIDDK account provides broader acquired-versus-genetic and generalized-versus-partial context. Neither source establishes a personal glucose, lipid, leptin or liver result, and research in selected populations is not an individual prognosis.
  • The four literal local inclusions remain Acquired generalized lipodystrophy (AGL), Berardinelli-Siep syndrome, Congenital generalized lipodystrophy (CGL) and Lawrence syndrome. The clinical NLM source uses the spelling Berardinelli-Seip; its spelling does not silently replace the stored or pinned wording. The local code-first, additional-code and exclusion arrays remain empty. Ancestor associated-condition and exclusion notes retain their original scopes, and no additional diagnosis, inherited mechanism or final code combination is assigned by this explanation.
  • The original E88.1 parent and neighboring entries provide classification navigation, not a collection of extra conditions. Six SNOMED relationships belong to the parent, with their original directions, source snapshot and additional-code or external-cause qualifiers. They do not establish an AKT2- or CIDEC-related disorder, a laminopathy, an acquired cause or a congenital condition on this leaf. Shared chapter excerpts concerning diabetes, pregnancy or obesity also do not diagnose those conditions in a reader. Keep navigation, qualified associations and the personal clinical account distinct.
Common workup
  • The actual history should establish what was observed, when it became apparent and which clinical interpretation the team recorded. Discuss existing reports and the person's real concerns rather than assuming that an early-life example describes every generalized entry. The code does not establish congenital onset, an acquired trigger, a particular physical appearance, a known mutation or a completed metabolic assessment. Questions about whether the congenital or acquired context is documented should remain separate from choosing investigations or inferring findings in a relative.
  • Ask what uncertainty an investigation is intended to resolve and how the result would affect the personal plan. A general discussion of genetic causes is not a universal gene-panel instruction, and a possible association with metabolic problems is not proof that those problems are present. ECG links do not establish a cardiac abnormality or order screening. The code also does not determine which measurements, imaging or follow-up tests are appropriate. Clinical justification and interpretation belong with the team that knows the actual history and findings.
  • This leaf retains G0429, three routine ECG associations, Q2026 and Q2028 in their original order and article contexts. The ECG rows distinguish tracing, interpretation/report and the combined service; they are not findings or a compulsory workup. G0429's facial/antiretroviral example does not establish facial involvement or treatment exposure in an individual. Q2026 describes RADIESSE in a 0.1 ML billing unit, and Q2028 describes SCULPTRA in a 0.5 MG unit. Those literal units are not administered doses, a product choice or proof of eligibility or current coverage.
  • When reviewing an existing report or proposed assessment, ask what was actually observed, what question remains open and who will explain the result. A code title, inclusion example or service description is not the result of that assessment. Missing information is not automatically a normal finding, and the absence of a particular related link does not establish that an investigation is unnecessary. The page cannot provide a diagnostic checklist for every subtype or a universal schedule; the clinical reason and documented context should remain visible.
Common management context
  • Care questions need the documented generalized-lipodystrophy context, current findings and the person's existing instructions. The historical NIDDK story about leptin research does not establish a present-day product indication, availability, eligibility or expected benefit for the reader. Ask what a proposed treatment is intended to address and what evidence applies to the person's specific situation. The code and its related-service links cannot choose replacement treatment, glucose or lipid medicines, cosmetic injections, dietary targets, a procedure or a monitoring schedule.
  • Clarify who will explain outstanding results and coordinate the personal plan, particularly if acquired-versus-congenital context remains unresolved. Keep the actual findings distinct from features listed for a named congenital syndrome in a general source. The code cannot predict severity, the development of an organ complication, treatment response or a relative's condition. A broadly described research outcome is not a promised outcome for an individual. Follow-up arrangements should come from the responsible team rather than a date or interval inferred from the classification.
  • An educational code page cannot determine the cause or urgency of a new health concern. Discuss a changing concern with the responsible clinical team and use the personal safety instructions they have provided; do not wait for a code or terminology question to be settled if medical attention is needed. This explanation does not replace assessment, establish that a symptom is harmless or supply a home rule for excluding another problem. Existing prescribed medicines and any changes to them require the appropriate treating team.
  • A useful shared discussion separates the documented problem, the goal of a proposed measure, the evidence applicable to that person and the arrangements for review. Ask which uncertainties remain and what alternatives need consideration. Neither an entry in this classification branch nor a historical research result selects a medicine, a dose, a dietary target, a genetic test, a cosmetic injection or an operation. No service association guarantees access, reimbursement or benefit, and no general reference promises a particular recovery or treatment response.

šŸ”Key distinctions

Important notes
  • The subtype distinctions do not establish a cause, gene, affected region, severity or an individual result. Partial and generalized contexts include both inherited and acquired examples; localized injection examples do not establish exposure. The grouping parent remains unchanged.
  • HIV-associated coding retains its code-first note and conditional adverse-effect wording. Those notes do not establish a drug cause, and a displayed incomplete stem is not a final encounter code. Parent notes and clinical-source terminology do not become extra diagnoses or silent repairs.
  • Qualified ECG and facial-filler associations remain billing context, not a prescribed workup, procedure performed, product indication, administered dose, eligibility or present coverage. Relevant references are selected separately for each leaf; no shared treatment pathway is assigned.
  • Five exact stored Index routes remain: the AGL and CGL main terms, generalized acquired/congenital lipodystrophy, and the named Berardinelli-Siep and Lawrence routes. They retain their original wording and hierarchy. A route does not establish a specific gene, an age of onset or the presence of every feature described by a clinical source. No clinical spelling is substituted into the stored Index, no route is moved to another page and no general source is used as authority to repair coding data.
  • The selected congenital-generalized NLM page was last updated in January 2019. The NIDDK research account is from April 2015, not a current drug label or comprehensive treatment guideline. The selected CMS conventions are historical FY2026 material, separate from the pinned FY2027 classification cross-check. These dates and narrower source populations remain explicit; they do not change stored release metadata or amount to a fresh specialist review of a person's condition.
  • All original notes, exclusions, inclusion terms, Index arrays, hierarchy, synonyms, URLs, source metadata, priorities, review flags, specialists, overrides, semantic caches and qualified service relationships remain available in their original places. This educational addition removes none of them and does not silently repair terminology, relationships or coding data. Reference selection is specific to the leaf: inherited, acquired, injection-related and HIV-associated examples are not presented as one common disease mechanism or treatment pathway. This is not individual clinical signoff or a current payment decision.
Related codes to consider
E88.10Lipodystrophy, unspecified
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.11Partial lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.13Localized lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.14HIV-associated lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.

Code hierarchy

chapter
4Endocrine, nutritional and metabolic diseases (E00-E89)
block
E70-E88Metabolic disorders
category
E88Other and unspecified metabolic disorders
category
E88.1Lipodystrophy, not elsewhere classified
currentE88.1

Official coding notes

Inclusion terms
  • Acquired generalized lipodystrophy (AGL)
  • Berardinelli-Siep syndrome
  • Congenital generalized lipodystrophy (CGL)
  • Lawrence syndrome

Where you may see this code

You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records.

Related specialists

EndocrinologistGeneral Physician

Coding guidelines

Common synonyms

Generalized lipodystrophy

Frequently asked questions

Code details

CodeE88.12
SystemICD10
Display nameGeneralized lipodystrophy
ChapterEndocrine, nutritional and metabolic diseases (E00-E89)
BlockMetabolic disorders

Flags

BillableYes
Valid clinical useYes

Source

SourceICD-10
Version2026-annual
Releaseannual
Year2026

Index terms

Matched terms
AGL(acquired generalized lipodystrophy)CGL(congenital generalized lipodystrophy)LipodystrophySyndromeSyndrome

About this content

This page is prepared by HealthAssure's clinical team using official coding standards from ICD-10. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.